IRIS
PATRIGNANI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.808
EU - Europa 8.518
AS - Asia 4.986
SA - Sud America 292
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 23
OC - Oceania 11
Totale 22.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.770
CN - Cina 1.906
UA - Ucraina 1.814
SG - Singapore 1.523
IE - Irlanda 1.431
TR - Turchia 1.215
GB - Regno Unito 1.204
IT - Italia 904
SE - Svezia 881
FR - Francia 794
DE - Germania 573
FI - Finlandia 360
RU - Federazione Russa 313
BR - Brasile 272
IN - India 184
PL - Polonia 95
CZ - Repubblica Ceca 47
BE - Belgio 45
HK - Hong Kong 45
CA - Canada 21
EU - Europa 21
VN - Vietnam 18
AT - Austria 15
IL - Israele 15
IR - Iran 13
NL - Olanda 13
MX - Messico 12
JP - Giappone 11
AU - Australia 9
EG - Egitto 9
IQ - Iraq 8
AE - Emirati Arabi Uniti 7
BD - Bangladesh 7
MA - Marocco 7
ZA - Sudafrica 7
AR - Argentina 6
GR - Grecia 6
RO - Romania 5
BY - Bielorussia 4
EC - Ecuador 4
AZ - Azerbaigian 3
CO - Colombia 3
KR - Corea 3
LT - Lituania 3
OM - Oman 3
PH - Filippine 3
PK - Pakistan 3
TH - Thailandia 3
UZ - Uzbekistan 3
BA - Bosnia-Erzegovina 2
CL - Cile 2
DZ - Algeria 2
ID - Indonesia 2
MN - Mongolia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ES - Italia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
JO - Giordania 1
KZ - Kazakistan 1
MY - Malesia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
SC - Seychelles 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 22.668
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.964
Chandler 1.728
Dublin 1.422
Southend 1.002
Singapore 875
Princeton 705
Izmir 638
Dearborn 568
Nanjing 494
Cambridge 323
Wilmington 311
Beijing 288
Nanchang 200
The Dalles 184
Altamura 171
Ashburn 162
Boardman 157
Santa Clara 151
Chieti 135
Shenyang 132
Woodbridge 119
Ann Arbor 114
Hebei 93
Kraków 93
Grevenbroich 83
Tianjin 78
Jiaxing 74
Kunming 72
Changsha 68
Munich 55
Los Angeles 54
Hangzhou 51
Norwalk 51
Hong Kong 44
Jinan 44
Brussels 41
Orange 39
Pescara 38
Brno 36
Helsinki 35
Washington 35
Kocaeli 31
Hefei 28
Ningbo 28
Guangzhou 27
Lanzhou 26
Rome 26
Zhengzhou 26
Shanghai 25
San Mateo 24
Augusta 23
São Paulo 23
Houston 22
Auburn Hills 21
Camerino 21
New York 21
Nuremberg 21
Moscow 19
Leawood 18
Dong Ket 17
Seattle 17
Spoltore 17
Taizhou 17
Düsseldorf 16
Romola 14
Changchun 13
Milan 13
Toronto 13
Fuzhou 12
Tavagnacco 12
Padova 11
Frontone 10
Hanover 10
Olomouc 10
Montesilvano 9
Ferrara 8
Lappeenranta 8
Tappahannock 8
Vienna 8
Viterbo 8
Ardabil 7
Lanciano 7
Menlo Park 7
Silvi 7
Torino 7
Cape Town 6
Falls Church 6
Frankfurt am Main 6
London 6
L’Aquila 6
Mexico City 6
Mugnano Di Napoli 6
Naples 6
Rio de Janeiro 6
Simi Valley 6
Verona 6
Walnut 6
Brasília 5
Cairo 5
Council Bluffs 5
Totale 13.730
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 194
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 129
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 118
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 112
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 112
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. 110
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 108
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 106
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 105
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 104
LA CASCATA DELL'ACIDO ARACHIDONICO 102
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 101
Thromboxane biosynthesis and pulmonary function in cystic fibrosis 100
Antithrombotic Agents and Cancer 99
Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF-β1 98
Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. 97
Rare SNP rs12731181 in the miR-590-3p Target Site of the Prostaglandin F2α Receptor Gene Confers Risk for Essential Hypertension in the Han Chinese Population. 97
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 96
Oxidative stress and platelet activation in essential hyperytension 95
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 94
null 93
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 93
Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. 93
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 92
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 92
Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting 92
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 92
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 91
Aspirin and Cancer 91
New insights into COX-2 biology and inhibition. 90
Platelet activation in patients with colorectal cancer. 90
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 90
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 89
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 89
Effetto del propranololo e del suo metabolita attivo 4-OH propranololo sui prostanoidi COX-2 derivati e sull’emossigenasi-1 (OH-1) in cellule HUVEC. 89
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 89
ALTERED RENAL AND PLATELET ARACHIDONIC ACID METABOLISM IN CIRRHOSIS. 88
T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. 87
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 87
Novel insights into the vasoprotective role of heme oxygenase-1. 86
Therapeutic targeting of dysregulated cellular communication. 86
Aspirin, platelet inhibition and cancer prevention. 86
A SELECTIVE THROMBOXANE-SYNTHASE INHIBITOR, ON PLATELET AND RENAL PROSTAGLANDIN ENDOPEROXIDE METABOLISM 85
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 85
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 85
Pharmacodynamic of cyclooxygenase inhibitors in humans. 85
Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. 85
NCX 4040, a Nitric Oxide-Donating Aspirin, Exerts Anti-Inflammatory Effects through Inhibition of I{kappa}B-{alpha} Degradation in Human Monocytes. 85
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 84
A comparison of low-dose aspirin and dazoxiben as selective inhibitors of thromboxane A2 production in man. 84
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 84
Mechanistic and pharmacological issues of aspirin as an anticancer agent 84
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 84
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 83
In vitro morphine metabolism by rat microglia. 83
A double-blind randomized study of the anti-platelet effects of low-dose ASA and placebo in patients after myocardial infarction 82
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 81
Induction of prostacyclin by steady laminar shear stress suppresses Tumor Necrosis Factor-alfa biosyntesis via Heme Oxygenase-1 in human endothelial cells. 81
INCREASED THROMBOXANE PRODUCTION BY MONOCYTE PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. 80
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 80
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. 80
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs 80
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 80
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 79
HIPK2 regulates beta-catenin level and transcriptional potential 79
Mechanistic aspects of COX-2 expression in colorectal neoplasia. 79
Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications 79
Usefulness of enzimatic intermediate markers-example of cox-2 inhibition 78
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 78
Repeated exposure to codeine alters morphine glucuronidation by affecting UGT gene expression in the rat. 78
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 77
ANTIINFLAMMATORY COMPOUNDS L-745,337 AND NS-398 ARE SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 IN HUMAN BLOOD MONOCYTES 77
IN VIVO FORMATION OF 8-ISO-PROSTAGLANDIN F2α AND ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN UNSTABLE ANGINA. 77
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 77
Low dose aspirin: how low, how often? 77
Clinical pharmacology of selective COX-2 inhibitors. 77
Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. 77
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. 77
Gut microbiota, host gene expression, and aging. 77
Increased thromboxane production by monocyte prostaglandin endoperoxide synthase-2 in patients with acute myocardial infarction (pubbl. su Suppl. Circulation) 76
RECOVERY OF THROMBOXANE BIOSYNTHESIS BY ASPIRIN-TREATED PLATELETS IN VITRO: A NOVEL MECHANISM OF ASPIRIN RESISTANCE. 76
INDUCTION OF PROSTACYCLIN BY STEADY LAMINAR SHEAR STRESS SUPPRESSES TUMOR NECROSIS FACTOR-ALPHA BIOSYNTHESIS VIA HEME OXYGENASE-1 IN HUMAN ENDOTHELIAL CELLS. 76
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 76
[ITALIAN CONSENSUS ON EULAR 2003 RECOMMENDATIONS FOR THE TREATMENT OF KNEE OSTEOARTHRITIS.] 76
New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia. 76
CYLOOXYGENASE-INDEPENDENT INDUCTION OF THE TUMOR SUPPRESSOR PROTEIN P21WAF-1/CIP1 AND DIFFERENTIATION BY L-745,337, A SELECTIVE COX-2 INHIBITOR, AND SODIUM SALICYLATE, IN HT-29 COLON CANCER CELLS. 75
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 75
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 75
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 75
A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. 75
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 75
ACTIVATED POLYMORPHONUCLEAR LEUKOCYTES INDUCE A PRO-INFLAMMATORY STATE OF THE ENDOTHELIUM 74
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 74
AMPLIFICATION LOOPS: THROMBOXANE GENERATION. 74
THE ROLE OF ARACHIDONIC ACID METABOLITE PGE2 ON T CELL PROLIFERATIVE RESPONSE. 74
Platelet-activating factor (PAF) receptor antagonists inhibit mitogen-induced human peripheral blood T-cell proliferation 74
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 74
P2Y12 Receptors in Tumorigenesis and Metastasis 74
FARMACI ANTIINFIAMMATORI NON STEROIDEI 73
Induction of prostaglandin endoperoxide synthase 2 in monocytes of human whole blood is associated with cyclooxigenase-dependent isoprostane formation 73
Totale 8.705
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.751
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.751
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020422 0 0 0 0 0 0 0 0 0 0 406 16
2020/20212.195 343 3 340 13 236 427 48 42 170 349 85 139
2021/20221.264 12 16 38 202 122 9 25 103 123 25 192 397
2022/20234.632 374 433 179 589 495 970 291 409 626 55 90 121
2023/20241.827 163 100 131 53 100 456 496 36 7 35 17 233
2024/20253.171 368 638 539 105 104 152 90 385 485 218 87 0
Totale 23.538